CONTACTS: Jacquie Ross, Investors (650) 358-1054 Mary Lynn Carver, Media (410) 443-1853
For Immediate Release
KITE ANNOUNCES YESCARTA® CAR T-CELL THERAPY IMPROVED EVENT-FREE SURVIVAL BY 60% OVER CHEMOTHERAPY PLUS STEM CELL TRANSPLANT IN SECONDLINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
— Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial to Test the Earlier Use of a CAR T-cell Therapy Against Standard of Care —
— Study Met the Primary and Key Secondary Endpoints of Event-Free Survival and Objective Response Rate, Demonstrating a Highly Statistically and Clinically Significant Improvement Compared to Standard of Care —
Santa Monica, Calif., – June 28, 2021 – Kite, a Gilead Company (Nasdaq: GILD), today announced top-line results from the primary analysis of ZUMA-7, a randomized Phase 3 global, multicenter study showing superiority of Yescarta® (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL). With a median follow-up of two years, the study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398, p <0.0001). The study also met the key secondary endpoint of objective response rate (ORR). The interim analysis of overall survival (OS) showed a trend favoring Yescarta; however, the data are immature at this time, and further analyses are planned for the future. Read more HERE.